SCHEMBL997426

SCHEMBL997426

[CH2]CCCCCCNC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5142057 1.00 EPHX1 (0.55)
SCHEMBL6235646 1.00 EPHX1 (0.55)
SCHEMBL16892582 1.00 EPHX1 (0.55)
SCHEMBL7453221 1.00 EPHX1 (0.55)
SCHEMBL198272 1.00
SCHEMBL1770447 1.00 EPHX1 (0.55)
SCHEMBL5073915 1.00 EPHX1 (0.55)
SCHEMBL5249016 1.00 EPHX1 (0.55)
SCHEMBL5246477 1.00 EPHX1 (0.55)
SCHEMBL434754 0.97

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1813636-A1 Polyamine analogs that activate antizyme frameshifting MediQuest Therapeutics, Inc. (US) 2007-08-01 EP claimed
EP-1730100-A1 POLYAMINE ANALOGS THAT ACTIVATE ANTIZYME FRAMESHIFTING MediQuest Therapeutics, Inc. (US) 2006-12-13 EP claimed
WO-2005105729-A1 POLYAMINE ANALOGS THAT ACTIVATE ANTIZYME FRAMESHIFTING MEDIQUEST THERAPEUTICS, INC. (US) 2005-11-10 WO claimed
US-20040209926-A1 Polyamine analogs that activate antizyme frameshifting MEDIQUEST THERAPEUTICS, INC. 2004-10-21 US claimed
US-20040058954-A1 Polyamine analogs that activate antizyme framshifting MEDIQUEST THERAPEUTICS, INC. 2004-03-25 US claimed
EP-3831372-A1 MITOGUAZONE FOR PREVENTING THE RELAPSE OR THE PROGRESSION OF MULTIPLE SCLEROSIS Pathologica LLC (US) 2021-06-09 EP disclosed
US-10350178-B2 Methods and compositions for treatment of demyelinating diseases PATHOLOGICA LLC (US) 2019-07-16 US disclosed
EP-3473247-A1 COMPOSITION FOR ORAL DELIVERY COMPRISING MGBG FOR USE IN TREATING MULTIPLE SCLEROSIS Pathologica LLC (US) 2019-04-24 EP disclosed
US-20180360783-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES PATHOLOGICA LLC 2018-12-20 US disclosed
EP-2453886-B1 PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE PATHOLOGICA LLC (US) 2018-12-12 EP disclosed
EP-2894685-B1 BENZOTHIENOBENZOTHIOPHENE DERIVATIVE, ORGANIC SEMICONDUCTOR MATERIAL, AND ORGANIC TRANSISTOR DAINIPPON INK & CHEMICALS (JP) 2018-10-31 EP disclosed
US-10085955-B2 Methods and compositions for treatment of demyelinating diseases PATHOLOGICA LLC (US) 2018-10-02 US disclosed
WO-2011009039-A2 PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE PATHOLOGICA LLC (US) 2011-01-20 WO disclosed
EP-1813636-A1 Polyamine analogs that activate antizyme frameshifting MediQuest Therapeutics, Inc. (US) 2007-08-01 EP disclosed
US-7144920-B2 Polyamine analogs that activate antizyme frameshifting MEDIQUEST THERAPEUTICS, INC. (US) 2006-12-05 US disclosed
US-6914079-B2 Polyamine analogs that activate antizyme frameshifting MEDIQUEST THERAPEUTICS, INC. (US) 2005-07-05 US disclosed
US-20040209926-A1 Polyamine analogs that activate antizyme frameshifting MEDIQUEST THERAPEUTICS, INC. 2004-10-21 US disclosed
US-6723745-B2 PREVENTION OR TREATMENT OF AUTOIMMUNE DISEASE IN WARM BLOODED ANIMAL SANKYO COMPANY, LIMITED (JP) 2004-04-20 US disclosed
US-20040058954-A1 Polyamine analogs that activate antizyme framshifting MEDIQUEST THERAPEUTICS, INC. 2004-03-25 US disclosed
EP-1167375-A1 ERYTHROMYCIN DERIVATIVES HOKURIKU SEIYAKU CO., LTD. (JP) 2002-01-02 EP disclosed